Compromised reconstitution capacity of Srsf2-mutated stem cells. (A) Percentage of CD45.2 donor cells in the PB of CD45.1 recipient mice after competitive transplantation using whole BM (mean ± SD, n = 10). (B) Chimerism of CD45.2 donor cells in myeloid (CD11b⁺ and/or Gr-1⁺), B-lymphoid (B220⁺), and T-lymphoid (CD4⁺ and/or CD8⁺) cells in PB (mean ± SD, n = 10). (C) Donor chimerism of stem and progenitor cell fractions in BM 18 weeks after competitive BMT (mean ± SD, n = 7). (D) Percentage of CD45.2 donor cells in PB of CD45.1 recipients after secondary transplantation (mean ± SD, n = 10). (E) Percentage of CD45.2 donor cells in PB after competitive transplantation using enriched LT-HSCs (CD34⁻KSL cells) (mean ± SD, n = 7). (F) Donor chimerism in PB after intra-BMT, indicated as mean ± SD (WT, n = 4; KI, n = 6). All of the transplantation experiments were performed in biological duplicate, and representative data are shown. *P < .05; **P < .01; ***P < .001; ****P < .0001. KI, Srsf2 mutant transplanted mice; WT, wild-type transplanted mice.